AMPK activation restores the stimulation of glucose uptake in an in vitro model of insulin-resistant cardiomyocytes via the activation of protein kinase B

1 Division of Cardiology, School of Medicine, Université Catholique de Louvain; and 2 Hormone and Metabolic Research Unit, Université Catholique de Louvain and Christian de Duve Institute of Cellular Pathology, Brussels, Belgium Submitted 1 December 2005 ; accepted in final form 10 February 2006 Dia...

Full description

Saved in:
Bibliographic Details
Published inAmerican journal of physiology. Heart and circulatory physiology Vol. 291; no. 1; pp. H239 - H250
Main Authors Bertrand, Luc, Ginion, Audrey, Beauloye, Christophe, Hebert, Alexandre D, Guigas, Bruno, Hue, Louis, Vanoverschelde, Jean-Louis
Format Journal Article
LanguageEnglish
Published United States 01.07.2006
Subjects
Online AccessGet full text
ISSN0363-6135
1522-1539
DOI10.1152/ajpheart.01269.2005

Cover

Abstract 1 Division of Cardiology, School of Medicine, Université Catholique de Louvain; and 2 Hormone and Metabolic Research Unit, Université Catholique de Louvain and Christian de Duve Institute of Cellular Pathology, Brussels, Belgium Submitted 1 December 2005 ; accepted in final form 10 February 2006 Diabetic hearts are known to be more susceptible to ischemic disease. Biguanides, like metformin, are known antidiabetic drugs that lower blood glucose concentrations by decreasing hepatic glucose production and increasing glucose disposal in muscle. Part of these metabolic effects is thought to be mediated by the activation of AMP-activated protein kinase (AMPK). In this work, we studied the relationship between AMPK activation and glucose uptake stimulation by biguanides and oligomycin, another AMPK activator, in both insulin-sensitive and insulin-resistant cardiomyocytes. In insulin-sensitive cardiomyocytes, insulin, biguanides and oligomycin were able to stimulate glucose uptake with the same efficiency. Stimulation of glucose uptake by insulin or biguanides was correlated to protein kinase B (PKB) or AMPK activation, respectively, and were additive. In insulin-resistant cardiomyocytes, where insulin stimulation of glucose uptake was greatly reduced, biguanides or oligomycin, in the absence of insulin, induced a higher stimulation of glucose uptake than that obtained in insulin-sensitive cells. This stimulation was correlated with the activation of both AMPK and PKB and was sensitive to the phosphatidylinositol-3-kinase/PKB pathway inhibitors. Finally, an adenoviral-mediated expression of a constitutively active form of AMPK increased both PKB phosphorylation and glucose uptake in insulin-resistant cardiomyocytes. We concluded that AMPK activators, like biguanides and oligomycin, are able to restore glucose uptake stimulation, in the absence of insulin, in insulin-resistant cardiomyocytes via the additive activation of AMPK and PKB. Our results suggest that AMPK activation could restore normal glucose metabolism in diabetic hearts and could be a potential therapeutic approach to treat insulin resistance. diabetes; AMP-activated protein kinase; metformin; oligomycin Address for reprint requests and other correspondence: L. Bertrand, Div. of Cardiology, Université Catholique de Louvain, Ave. Hippocrate, 55, CARD5550, B-1200 Brussels, Belgium (e-mail: bertrand{at}card.ucl.ac.be )
AbstractList Diabetic hearts are known to be more susceptible to ischemic disease. Biguanides, like metformin, are known antidiabetic drugs that lower blood glucose concentrations by decreasing hepatic glucose production and increasing glucose disposal in muscle. Part of these metabolic effects is thought to be mediated by the activation of AMP-activated protein kinase (AMPK). In this work, we studied the relationship between AMPK activation and glucose uptake stimulation by biguanides and oligomycin, another AMPK activator, in both insulin-sensitive and insulin-resistant cardiomyocytes. In insulin-sensitive cardiomyocytes, insulin, biguanides and oligomycin were able to stimulate glucose uptake with the same efficiency. Stimulation of glucose uptake by insulin or biguanides was correlated to protein kinase B (PKB) or AMPK activation, respectively, and were additive. In insulin-resistant cardiomyocytes, where insulin stimulation of glucose uptake was greatly reduced, biguanides or oligomycin, in the absence of insulin, induced a higher stimulation of glucose uptake than that obtained in insulin-sensitive cells. This stimulation was correlated with the activation of both AMPK and PKB and was sensitive to the phosphatidylinositol-3-kinase/PKB pathway inhibitors. Finally, an adenoviral-mediated expression of a constitutively active form of AMPK increased both PKB phosphorylation and glucose uptake in insulin-resistant cardiomyocytes. We concluded that AMPK activators, like biguanides and oligomycin, are able to restore glucose uptake stimulation, in the absence of insulin, in insulin-resistant cardiomyocytes via the additive activation of AMPK and PKB. Our results suggest that AMPK activation could restore normal glucose metabolism in diabetic hearts and could be a potential therapeutic approach to treat insulin resistance.
1 Division of Cardiology, School of Medicine, Université Catholique de Louvain; and 2 Hormone and Metabolic Research Unit, Université Catholique de Louvain and Christian de Duve Institute of Cellular Pathology, Brussels, Belgium Submitted 1 December 2005 ; accepted in final form 10 February 2006 Diabetic hearts are known to be more susceptible to ischemic disease. Biguanides, like metformin, are known antidiabetic drugs that lower blood glucose concentrations by decreasing hepatic glucose production and increasing glucose disposal in muscle. Part of these metabolic effects is thought to be mediated by the activation of AMP-activated protein kinase (AMPK). In this work, we studied the relationship between AMPK activation and glucose uptake stimulation by biguanides and oligomycin, another AMPK activator, in both insulin-sensitive and insulin-resistant cardiomyocytes. In insulin-sensitive cardiomyocytes, insulin, biguanides and oligomycin were able to stimulate glucose uptake with the same efficiency. Stimulation of glucose uptake by insulin or biguanides was correlated to protein kinase B (PKB) or AMPK activation, respectively, and were additive. In insulin-resistant cardiomyocytes, where insulin stimulation of glucose uptake was greatly reduced, biguanides or oligomycin, in the absence of insulin, induced a higher stimulation of glucose uptake than that obtained in insulin-sensitive cells. This stimulation was correlated with the activation of both AMPK and PKB and was sensitive to the phosphatidylinositol-3-kinase/PKB pathway inhibitors. Finally, an adenoviral-mediated expression of a constitutively active form of AMPK increased both PKB phosphorylation and glucose uptake in insulin-resistant cardiomyocytes. We concluded that AMPK activators, like biguanides and oligomycin, are able to restore glucose uptake stimulation, in the absence of insulin, in insulin-resistant cardiomyocytes via the additive activation of AMPK and PKB. Our results suggest that AMPK activation could restore normal glucose metabolism in diabetic hearts and could be a potential therapeutic approach to treat insulin resistance. diabetes; AMP-activated protein kinase; metformin; oligomycin Address for reprint requests and other correspondence: L. Bertrand, Div. of Cardiology, Université Catholique de Louvain, Ave. Hippocrate, 55, CARD5550, B-1200 Brussels, Belgium (e-mail: bertrand{at}card.ucl.ac.be )
Diabetic hearts are known to be more susceptible to ischemic disease. Biguanides, like metformin, are known antidiabetic drugs that lower blood glucose concentrations by decreasing hepatic glucose production and increasing glucose disposal in muscle. Part of these metabolic effects is thought to be mediated by the activation of AMP-activated protein kinase (AMPK). In this work, we studied the relationship between AMPK activation and glucose uptake stimulation by biguanides and oligomycin, another AMPK activator, in both insulin-sensitive and insulin-resistant cardiomyocytes. In insulin-sensitive cardiomyocytes, insulin, biguanides and oligomycin were able to stimulate glucose uptake with the same efficiency. Stimulation of glucose uptake by insulin or biguanides was correlated to protein kinase B (PKB) or AMPK activation, respectively, and were additive. In insulin-resistant cardiomyocytes, where insulin stimulation of glucose uptake was greatly reduced, biguanides or oligomycin, in the absence of insulin, induced a higher stimulation of glucose uptake than that obtained in insulin-sensitive cells. This stimulation was correlated with the activation of both AMPK and PKB and was sensitive to the phosphatidylinositol-3-kinase/PKB pathway inhibitors. Finally, an adenoviral-mediated expression of a constitutively active form of AMPK increased both PKB phosphorylation and glucose uptake in insulin-resistant cardiomyocytes. We concluded that AMPK activators, like biguanides and oligomycin, are able to restore glucose uptake stimulation, in the absence of insulin, in insulin-resistant cardiomyocytes via the additive activation of AMPK and PKB. Our results suggest that AMPK activation could restore normal glucose metabolism in diabetic hearts and could be a potential therapeutic approach to treat insulin resistance.Diabetic hearts are known to be more susceptible to ischemic disease. Biguanides, like metformin, are known antidiabetic drugs that lower blood glucose concentrations by decreasing hepatic glucose production and increasing glucose disposal in muscle. Part of these metabolic effects is thought to be mediated by the activation of AMP-activated protein kinase (AMPK). In this work, we studied the relationship between AMPK activation and glucose uptake stimulation by biguanides and oligomycin, another AMPK activator, in both insulin-sensitive and insulin-resistant cardiomyocytes. In insulin-sensitive cardiomyocytes, insulin, biguanides and oligomycin were able to stimulate glucose uptake with the same efficiency. Stimulation of glucose uptake by insulin or biguanides was correlated to protein kinase B (PKB) or AMPK activation, respectively, and were additive. In insulin-resistant cardiomyocytes, where insulin stimulation of glucose uptake was greatly reduced, biguanides or oligomycin, in the absence of insulin, induced a higher stimulation of glucose uptake than that obtained in insulin-sensitive cells. This stimulation was correlated with the activation of both AMPK and PKB and was sensitive to the phosphatidylinositol-3-kinase/PKB pathway inhibitors. Finally, an adenoviral-mediated expression of a constitutively active form of AMPK increased both PKB phosphorylation and glucose uptake in insulin-resistant cardiomyocytes. We concluded that AMPK activators, like biguanides and oligomycin, are able to restore glucose uptake stimulation, in the absence of insulin, in insulin-resistant cardiomyocytes via the additive activation of AMPK and PKB. Our results suggest that AMPK activation could restore normal glucose metabolism in diabetic hearts and could be a potential therapeutic approach to treat insulin resistance.
Author Hue, Louis
Hebert, Alexandre D
Bertrand, Luc
Vanoverschelde, Jean-Louis
Ginion, Audrey
Beauloye, Christophe
Guigas, Bruno
Author_xml – sequence: 1
  fullname: Bertrand, Luc
– sequence: 2
  fullname: Ginion, Audrey
– sequence: 3
  fullname: Beauloye, Christophe
– sequence: 4
  fullname: Hebert, Alexandre D
– sequence: 5
  fullname: Guigas, Bruno
– sequence: 6
  fullname: Hue, Louis
– sequence: 7
  fullname: Vanoverschelde, Jean-Louis
BackLink https://www.ncbi.nlm.nih.gov/pubmed/16489105$$D View this record in MEDLINE/PubMed
BookMark eNp9kc1u1DAUhS1URKcDT4CEvGKXIbbzZ3aloi2iCBZlbXmS64lbxw62MzCvwtPWmekPQoLN9eKe79x7fU7QkXUWEHpN8hUhJX0nb8YepI-rnNCKr2iel8_QInVoRkrGj9AiZxXLKsLKY3QSwk2eFHXFXqBjUhUNJ3m5QL9Pv3z7jGUb9VZG7Sz2EKJLBccecIh6mMyh4RTemKl1AfA0RnkLWFss7Vy3OnqHB9eBmWXahslomyUXHaK0EbfSd9oNO9fuYrLearm3_2NswkbvIiS3W21lGvLhJXqupAnw6v5dou_nH6_PLrOrrxefzk6vsrYoecygbbo1L6CWrKBcgWwVVYooydayUZR1tChlVdcAvGasa8qqLFhDgQPhFWeKLdHbg29a4MeUzheDDi0YIy24KYiqyWsyQ0v05l44rQfoxOj1IP1OPPxmEvCDoPUuBA9KtDru74teaiNILubkxENyYp-cmJNLLPuLfbT_L7U6UL3e9D-1BzH2u6CdcZvdE0A5EURcUsYT8P7fwPlkzDX8io_kEyjGTrE78ZbJBA
CitedBy_id crossref_primary_10_3390_foods10061266
crossref_primary_10_1242_jcs_041178
crossref_primary_10_1152_ajpheart_00329_2006
crossref_primary_10_1096_fj_201901440RR
crossref_primary_10_1152_ajpheart_00664_2021
crossref_primary_10_1111_1744_7917_12795
crossref_primary_10_1152_ajpheart_00002_2007
crossref_primary_10_3390_antiox11040723
crossref_primary_10_1016_j_hermed_2019_100282
crossref_primary_10_2147_DDDT_S409373
crossref_primary_10_1155_2013_429207
crossref_primary_10_1007_s40256_018_0266_3
crossref_primary_10_2217_clp_09_43
crossref_primary_10_1038_s41392_025_02141_x
crossref_primary_10_3389_fphar_2022_930308
crossref_primary_10_1002_jcb_30433
crossref_primary_10_1111_j_1365_2443_2011_01517_x
crossref_primary_10_3390_ijms19102869
crossref_primary_10_1248_bpb_b17_01027
crossref_primary_10_1074_jbc_M802869200
crossref_primary_10_1152_ajpcell_00073_2014
crossref_primary_10_1152_ajpheart_00736_2019
crossref_primary_10_1016_j_mce_2012_03_013
crossref_primary_10_1016_j_biopha_2021_112538
crossref_primary_10_1111_jcmm_12220
crossref_primary_10_3390_biom11121834
crossref_primary_10_1002_ehf2_12937
crossref_primary_10_1016_j_numecd_2007_01_007
crossref_primary_10_1038_s41467_017_02795_4
crossref_primary_10_1016_j_yjmcc_2012_11_005
crossref_primary_10_1016_j_numecd_2017_04_009
crossref_primary_10_1007_s11897_012_0102_z
crossref_primary_10_1016_j_bbadis_2014_10_016
crossref_primary_10_1016_j_bbadis_2013_02_015
crossref_primary_10_1016_j_mce_2019_110642
crossref_primary_10_1002_iub_1063
crossref_primary_10_1016_j_jep_2015_05_003
crossref_primary_10_1016_S1734_1140_11_70635_1
crossref_primary_10_1074_jbc_M112_363630
crossref_primary_10_1113_EP085091
crossref_primary_10_1007_s00424_020_02444_8
crossref_primary_10_1177_1559827612465576
crossref_primary_10_1210_en_2009_0624
crossref_primary_10_1152_ajpregu_90590_2008
crossref_primary_10_1016_j_plefa_2012_04_009
crossref_primary_10_1007_s00424_019_02285_0
crossref_primary_10_1152_ajpheart_00210_2014
crossref_primary_10_1161_RES_0000000000000097
crossref_primary_10_3109_10409238_2010_488215
crossref_primary_10_1152_ajpheart_00449_2022
crossref_primary_10_1016_j_bbalip_2016_04_008
crossref_primary_10_2337_db11_1132
crossref_primary_10_1016_j_biopha_2023_115271
crossref_primary_10_1007_s40256_022_00545_6
crossref_primary_10_1152_ajprenal_00034_2011
crossref_primary_10_1152_ajpendo_00160_2011
crossref_primary_10_1093_cvr_cvn093
crossref_primary_10_1016_j_bbamcr_2012_08_009
crossref_primary_10_1152_ajpendo_00158_2021
crossref_primary_10_1097_HCO_0b013e3282fcc2fa
crossref_primary_10_3390_ph17070920
crossref_primary_10_1016_j_cmet_2014_09_018
crossref_primary_10_1080_21623945_2018_1525252
crossref_primary_10_1152_ajpheart_00738_2016
crossref_primary_10_1016_j_cbi_2022_110265
crossref_primary_10_1038_srep41166
crossref_primary_10_1093_cvr_cvt227
crossref_primary_10_3390_jcm10040721
crossref_primary_10_1007_s00360_013_0743_6
crossref_primary_10_1016_j_yjmcc_2012_12_015
crossref_primary_10_3390_cells10040905
crossref_primary_10_1016_j_diabres_2017_12_011
crossref_primary_10_12997_jla_2020_9_1_92
crossref_primary_10_1113_expphysiol_2006_034736
crossref_primary_10_1152_ajpheart_00058_2022
crossref_primary_10_1016_j_bbagen_2009_09_005
crossref_primary_10_1016_j_bbrc_2008_09_057
crossref_primary_10_1152_ajpheart_00873_2007
crossref_primary_10_1161_CIRCULATIONAHA_124_067876
crossref_primary_10_1152_ajpheart_00986_2010
crossref_primary_10_1016_j_numecd_2008_09_002
crossref_primary_10_1111_1755_5922_12482
crossref_primary_10_1152_ajpheart_01032_2005
crossref_primary_10_1093_cvr_cvr230
crossref_primary_10_1161_CIRCRESAHA_118_311371
crossref_primary_10_1161_JAHA_118_011640
crossref_primary_10_1038_nrd3431
crossref_primary_10_1161_CIRCRESAHA_113_302095
crossref_primary_10_1155_2016_2594703
crossref_primary_10_1016_j_ijcard_2008_04_010
crossref_primary_10_1111_ijd_16873
crossref_primary_10_1152_ajpheart_00965_2013
crossref_primary_10_1016_j_acvd_2020_06_006
crossref_primary_10_1016_j_febslet_2010_06_004
crossref_primary_10_1124_mol_108_050104
crossref_primary_10_1210_en_2007_1326
crossref_primary_10_1016_j_peptides_2010_04_009
crossref_primary_10_1152_ajpendo_00421_2009
crossref_primary_10_1016_j_apsb_2020_10_007
crossref_primary_10_1007_s00018_012_1198_8
crossref_primary_10_1161_CIRCHEARTFAILURE_108_821892
crossref_primary_10_1042_CS20080066
crossref_primary_10_1042_BSR20181995
crossref_primary_10_1152_ajpendo_00427_2011
crossref_primary_10_1042_BJ20120060
crossref_primary_10_1161_CIRCRESAHA_108_190918
crossref_primary_10_1016_j_bbalip_2016_03_014
crossref_primary_10_1111_jpi_12064
crossref_primary_10_1017_S0954422421000056
crossref_primary_10_1016_j_diabres_2019_107879
crossref_primary_10_1016_j_hfc_2012_06_002
crossref_primary_10_1021_acs_jafc_9b04274
Cites_doi 10.1016/S0014-5793(01)02788-0
10.1161/01.RES.88.5.513
10.2337/diabetes.54.7.2179
10.1161/01.CIR.59.1.8
10.2337/diab.47.8.1281
10.1128/MCB.20.18.6704-6711.2000
10.1074/jbc.M503824200
10.1185/030079905X50606
10.1016/j.tcm.2005.04.005
10.2337/diab.46.3.524
10.1007/s001250051644
10.1056/NEJM199602293340906
10.1007/s00125-005-0016-3
10.1172/JCI10583
10.1152/ajpendo.00382.2002
10.1172/JCI6928
10.1111/j.1432-1033.1989.tb15186.x
10.1074/jbc.275.1.223
10.2337/diabetes.51.2.443
10.1046/j.1432-1327.1998.2580277.x
10.1128/MCB.26.1.63-76.2006
10.1016/j.cmet.2005.06.005
10.1242/jcs.01540
10.1016/j.biochi.2004.10.017
10.1042/bst0310213
10.1042/BJ20040885
10.1210/endo.131.3.1505458
10.1172/JCI200112348
10.1042/BST0330354
10.1074/jbc.M201494200
10.1152/ajpendo.00443.2005
10.2337/diabetes.49.4.647
10.1016/j.cub.2003.10.031
10.1042/bj20030048
10.1016/j.cmet.2005.05.009
10.1074/jbc.271.37.22289
10.2337/diabetes.51.8.2420
10.1074/jbc.M202489200
10.2337/diabetes.51.4.1110
10.2337/diabetes.54.8.2360
10.2337/diabetes.49.12.2063
10.1074/jbc.C100483200
10.1016/S0006-2952(02)01509-5
10.1016/S0960-9822(00)00742-9
10.1172/JCI13505
10.1152/ajpheart.1999.277.2.H643
10.1210/endo.136.2.7835271
10.2337/diabetes.53.12.3258
10.7326/0003-4819-131-4-199908170-00008
10.1074/jbc.274.43.30927
10.1038/sj.bjp.0704878
10.1016/j.lfs.2003.08.040
10.1042/BST0330346
10.2174/1566524053766103
10.1074/jbc.M506850200
10.2337/diabetes.54.3.803
10.1186/1475-4924-2-28
10.1074/jbc.272.12.7759
10.2337/diab.37.12.1595
10.2337/diabetes.52.5.1066
10.1042/bj1740603
10.1152/ajpheart.00374.2004
10.1016/S0140-6736(98)07037-8
ContentType Journal Article
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1152/ajpheart.01269.2005
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList CrossRef
MEDLINE

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Anatomy & Physiology
EISSN 1522-1539
EndPage H250
ExternalDocumentID 16489105
10_1152_ajpheart_01269_2005
ajpheart_291_1_H239
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID -
02
23M
2WC
39C
4.4
53G
5GY
5VS
8M5
ABFLS
ABPTK
ACIWK
ACPRK
ADACO
ADBBV
AENEX
AFFNX
AFRAH
ALMA_UNASSIGNED_HOLDINGS
BAWUL
BKOMP
C1A
DIK
DL
E3Z
EBS
EJD
F5P
GX1
H13
KQ8
O0-
OK1
P2P
PQEST
PQQKQ
RAP
RHF
RHI
RPL
UKR
WH7
WOQ
---
3O-
6J9
AAFWJ
AAYXX
ABJNI
ACBEA
BKKCC
BTFSW
CITATION
EMOBN
ITBOX
RPRKH
TR2
W8F
XSW
YSK
YYP
~02
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ID FETCH-LOGICAL-c459t-ec8db94e7a3429feacf2ff1fa3ba8f23d245a677ee9733d85654382e9e19693f3
ISSN 0363-6135
IngestDate Thu Jul 10 16:58:17 EDT 2025
Sat Sep 28 07:47:23 EDT 2024
Tue Jul 01 04:20:03 EDT 2025
Thu Apr 24 23:09:15 EDT 2025
Tue Jan 05 17:57:06 EST 2021
Mon May 06 11:36:58 EDT 2019
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c459t-ec8db94e7a3429feacf2ff1fa3ba8f23d245a677ee9733d85654382e9e19693f3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 16489105
PQID 68071654
PQPubID 23479
ParticipantIDs pubmed_primary_16489105
crossref_primary_10_1152_ajpheart_01269_2005
highwire_physiology_ajpheart_291_1_H239
crossref_citationtrail_10_1152_ajpheart_01269_2005
proquest_miscellaneous_68071654
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2006-07-01
PublicationDateYYYYMMDD 2006-07-01
PublicationDate_xml – month: 07
  year: 2006
  text: 2006-07-01
  day: 01
PublicationDecade 2000
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle American journal of physiology. Heart and circulatory physiology
PublicationTitleAlternate Am J Physiol Heart Circ Physiol
PublicationYear 2006
References R56A
R61
R60
R63
R62
R21
R20
R64
R23
R22
R25
R24
R27
R26
R29
R28
R1
R2
R3
R4
R5
R7
R8
R9
R30
R32
R31
R34
R33
R36
R35
R38
R37
R39
R41
R40
R43
R42
R45
R44
R47
R46
R49
R48
R50
R52
R51
R10
R54
R53
R12
R56
R11
R55
R14
R58
R13
R57
R16
R15
R59
R18
R17
R19
References_xml – ident: R5
  doi: 10.1016/S0014-5793(01)02788-0
– ident: R4
  doi: 10.1161/01.RES.88.5.513
– ident: R17
  doi: 10.2337/diabetes.54.7.2179
– ident: R34
  doi: 10.1161/01.CIR.59.1.8
– ident: R38
  doi: 10.2337/diab.47.8.1281
– ident: R60
  doi: 10.1128/MCB.20.18.6704-6711.2000
– ident: R32
  doi: 10.1074/jbc.M503824200
– ident: R1
  doi: 10.1185/030079905X50606
– ident: R63
  doi: 10.1016/j.tcm.2005.04.005
– ident: R8
  doi: 10.2337/diab.46.3.524
– ident: R14
  doi: 10.1007/s001250051644
– ident: R2
  doi: 10.1056/NEJM199602293340906
– ident: R43
  doi: 10.1007/s00125-005-0016-3
– ident: R51
  doi: 10.1172/JCI10583
– ident: R58
  doi: 10.1152/ajpendo.00382.2002
– ident: R36
  doi: 10.1172/JCI6928
– ident: R12
  doi: 10.1111/j.1432-1033.1989.tb15186.x
– ident: R19
  doi: 10.1074/jbc.275.1.223
– ident: R35
  doi: 10.2337/diabetes.51.2.443
– ident: R16
  doi: 10.1046/j.1432-1327.1998.2580277.x
– ident: R56
  doi: 10.1128/MCB.26.1.63-76.2006
– ident: R61
  doi: 10.1016/j.cmet.2005.06.005
– ident: R23
  doi: 10.1242/jcs.01540
– ident: R11
  doi: 10.1016/j.biochi.2004.10.017
– ident: R29
  doi: 10.1042/bst0310213
– ident: R22
  doi: 10.1042/BJ20040885
– ident: R30
  doi: 10.1210/endo.131.3.1505458
– ident: R54
  doi: 10.1172/JCI200112348
– ident: R9
  doi: 10.1042/BST0330354
– ident: R45
  doi: 10.1074/jbc.M201494200
– ident: R50
  doi: 10.1152/ajpendo.00443.2005
– ident: R49
  doi: 10.2337/diabetes.49.4.647
– ident: R62
  doi: 10.1016/j.cub.2003.10.031
– ident: R57
– ident: R48
  doi: 10.1042/bj20030048
– ident: R27
  doi: 10.1016/j.cmet.2005.05.009
– ident: R42
  doi: 10.1074/jbc.271.37.22289
– ident: R26
  doi: 10.2337/diabetes.51.8.2420
– ident: R21
  doi: 10.1074/jbc.M202489200
– ident: R52
  doi: 10.2337/diabetes.51.4.1110
– ident: R55
  doi: 10.2337/diabetes.54.8.2360
– ident: R31
  doi: 10.2337/diabetes.49.12.2063
– ident: R33
  doi: 10.1074/jbc.C100483200
– ident: R39
  doi: 10.1016/S0006-2952(02)01509-5
– ident: R44
  doi: 10.1016/S0960-9822(00)00742-9
– ident: R64
  doi: 10.1172/JCI13505
– ident: R47
  doi: 10.1152/ajpheart.1999.277.2.H643
– ident: R20
  doi: 10.1210/endo.136.2.7835271
– ident: R13
  doi: 10.2337/diabetes.53.12.3258
– ident: R15
  doi: 10.7326/0003-4819-131-4-199908170-00008
– ident: R7
  doi: 10.1074/jbc.274.43.30927
– ident: R40
  doi: 10.1038/sj.bjp.0704878
– ident: R41
  doi: 10.1016/j.lfs.2003.08.040
– ident: R59
  doi: 10.1042/BST0330346
– ident: R3
  doi: 10.2174/1566524053766103
– ident: R28
  doi: 10.1074/jbc.M506850200
– ident: R18
  doi: 10.2337/diabetes.54.3.803
– ident: R25
  doi: 10.1186/1475-4924-2-28
– ident: R53
  doi: 10.1074/jbc.272.12.7759
– ident: R46
  doi: 10.2337/diab.37.12.1595
– ident: R37
  doi: 10.2337/diabetes.52.5.1066
– ident: R10
  doi: 10.1042/bj1740603
– ident: R24
  doi: 10.1152/ajpheart.00374.2004
– ident: R56A
  doi: 10.1016/S0140-6736(98)07037-8
SSID ssj0005763
Score 2.243452
Snippet 1 Division of Cardiology, School of Medicine, Université Catholique de Louvain; and 2 Hormone and Metabolic Research Unit, Université Catholique de Louvain and...
Diabetic hearts are known to be more susceptible to ischemic disease. Biguanides, like metformin, are known antidiabetic drugs that lower blood glucose...
SourceID proquest
pubmed
crossref
highwire
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage H239
SubjectTerms AMP-Activated Protein Kinases
Animals
Biguanides - administration & dosage
Cells, Cultured
Dose-Response Relationship, Drug
Drug Combinations
Enzyme Activation
Glucose - metabolism
Insulin - administration & dosage
Insulin Resistance - physiology
Male
Multienzyme Complexes - drug effects
Multienzyme Complexes - metabolism
Myocytes, Cardiac - metabolism
Oligomycins - administration & dosage
Protein-Serine-Threonine Kinases - drug effects
Protein-Serine-Threonine Kinases - metabolism
Proto-Oncogene Proteins c-akt - metabolism
Rats
Rats, Wistar
Title AMPK activation restores the stimulation of glucose uptake in an in vitro model of insulin-resistant cardiomyocytes via the activation of protein kinase B
URI http://ajpheart.physiology.org/cgi/content/abstract/291/1/H239
https://www.ncbi.nlm.nih.gov/pubmed/16489105
https://www.proquest.com/docview/68071654
Volume 291
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAFT
  databaseName: Open Access Digital Library
  customDbUrl:
  eissn: 1522-1539
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0005763
  issn: 0363-6135
  databaseCode: KQ8
  dateStart: 19971001
  isFulltext: true
  titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html
  providerName: Colorado Alliance of Research Libraries
– providerCode: PRVFQY
  databaseName: GFMER Free Medical Journals
  customDbUrl:
  eissn: 1522-1539
  dateEnd: 20240930
  omitProxy: true
  ssIdentifier: ssj0005763
  issn: 0363-6135
  databaseCode: GX1
  dateStart: 19971001
  isFulltext: true
  titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php
  providerName: Geneva Foundation for Medical Education and Research
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEF6FIiEuCFoeKa89IDiAQ_1YP44BAREQ1EMq5Wat7bUwJXbk2pXCT-GP8XeY2YftKCkCLlZk785amc-e2fHMN4Q8CzPHS8ESWF4uctigeMziKYus7IQlmZsyziVPwfyLPzvzPi7ZcjT6Nchaaptkkv7YW1fyP1qFc6BXrJL9B812QuEE_Ab9whE0DMe_0vF0fvpJsmGouOrLWraJQdKGr0gcW6x0by70CE1uertu-LlkCuEyyfGyaOpKNcRR9BEyN90CKehZlg1yV2dFtdpU6QZjtJcFl-IHy2LSNNI9gLTzogSzqFs5G3Jb81FowFIhAyoyoj_BSqha5bmnRY1psfK7fz-iixiIuql1HubnNu0yh4qy0I2x26wWg-G8xWbG2xQKfew30dVKusSnFjr5eRACCUwIxJR-ubAHVrwn5rXuRPYOftVLeuYo_qRd68GQjZZ_W2Mz8WYCttuXtUxsOBogsF5JQMFOMwRvi_WmtEtwNJeuketO4PvYWuPDcpB7FKgWf-a-NR0WrP96z-pIbKvlbXtPhtH66t2R9JIWt8ktvb2hU4XVO2QkykNyNC1Bp6sNfU5PO60ekhtznddxRH4ikmkPKWqQTAFqdIBkWuVUI5kqJNOipLzEo0QylUjGYTtIpttIhvFcih8sC9M0kqlCMn1zl5y9f7d4O7N01xAr9VjUWCINsyTyRMBd8LVycCxyJ8_tnLsJD3PHhZcT434QCBEFrpuFDKurQ0dEApmi3Ny9Rw7KqhQPCMVch8wLE-57kYfEk8KxE7BYke36J8JmY-IYbcSpptTHzi7fY7m1Zk5stBlLbWLPV5j0qpu0Vowyfx7uGjXH_ZMXY4BqAZjrpgDcYztGaMfrLB-TF_tmdfL70WPy1GAnBsuCnwt5Kar2IvZD2H7AnzMm9xWk-tvVaDy-8spDcrN_UB-Rg6ZuxWPw3pvkiXwSfgOsWvra
linkProvider Geneva Foundation for Medical Education and Research
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=AMPK+activation+restores+the+stimulation+of+glucose+uptake+in+an+in+vitro+model+of+insulin-resistant+cardiomyocytes+via+the+activation+of+protein+kinase+B&rft.jtitle=American+journal+of+physiology.+Heart+and+circulatory+physiology&rft.au=Bertrand%2C+Luc&rft.au=Ginion%2C+Audrey&rft.au=Beauloye%2C+Christophe&rft.au=Hebert%2C+Alexandre+D&rft.date=2006-07-01&rft.issn=0363-6135&rft.volume=291&rft.issue=1&rft.spage=H239&rft_id=info:doi/10.1152%2Fajpheart.01269.2005&rft_id=info%3Apmid%2F16489105&rft.externalDocID=16489105
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0363-6135&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0363-6135&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0363-6135&client=summon